Posters

Posters
Exposure–Response Analysis to Compare Changes in the Clinical Endpoints for Tardive Dyskinesia and Chorea in Huntington Disease Following Once-Daily and Twice-Daily Tablet Formulations of Deutetrabenazine

Exposure-Response models using predicted exposure of deutetrabenazine’s active metabolites following BID and QD formulation administration, and therapeutic responses in the phase 3 TD and HD studies of the BID formulation were leveraged to predict changes in clinical efficacy endpoints following QD formulation administration in patients.

Posters
Drug–Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

This study estimated proportions of patients with TD at risk of DDIs with valbenazine/deutetrabenazine in real-world practice.